60 Degrees Pharmaceuticals exercises license option for castanospermine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
January 28, 2026 8:01 AM ESTWASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (60 Degrees Pharma or the Company), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced it has exercised the option in its agreement with Florida State University (FSU) to negotiate an exclusive license to use large-scale purification techniques to extract castanospermine from the seeds of Castanospermum australe... More
